glp-1 manufacturers Agonists Market Report 2025-2033, By Product, Molecule, and Geo Compounded GLP-1 Drugs and its

The most successful treatments currently available include glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), exemplified by semaglutide (approved in 2017, $19.9 billion sales in 2023) 3 and tirzepatide (approved in 2022, $5.3 billion sales in 2023) 4

each vial is a 30-day supply at the indicated dose

GLP-1 receptor agonists resistant to DPP-4 degradation such as semaglutide, albiglutide, and dulaglutide have been developed, generating an extended half-life in circulation [15]

Needle-free option On-demand use Desire support How PT-141 Nasal Spray Works Supports sexual response by activating pathways in the brain associated with desire and arousal